Filing Details
- Accession Number:
- 0001209191-14-058497
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-09-17 20:58:48
- Reporting Period:
- 2014-09-16
- Filing Date:
- 2014-09-17
- Accepted Time:
- 2014-09-17 20:58:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1463729 | Receptos Inc. | RCPT | Pharmaceutical Preparations (2834) | 264190792 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1396943 | K Graham Cooper | 10835 Road To The Cure, Suite 205 San Diego CA 92121 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-09-16 | 50,000 | $5.10 | 50,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-09-16 | 50,000 | $61.30 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2014-09-16 | 50,000 | $0.00 | 50,000 | $5.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 96,666 | 2023-02-15 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.38 to $62.31 per share, inclusive. The reporting person undertakes to provide to Receptos, Inc., any security holder of Receptos, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The option, representing a right to purchase a total of 146,666 shares, became exercisable as follows: (i) 106,666 shares vested 25% on the one-year anniversary of February 15, 2013 and 1/48th of the shares vest each month thereafter for the remaining three years; and (ii) commencement of vesting on the remaining 40,000 shares was subject to the fulfillment of a milestone event consisting of the dosing of the first patient in Receptos' first clinical trial for a product candidate where the FDA (or foreign equivalent) would recognize such a clinical trial, assuming successful completion, as a pivotal study for a product candidate for submission of a new Drug Application or a Biologics License Application, and any Phase 3 clinical study will be presumed to satisfy this requirement. (Continued in footnote 4)
- The shares vested 25% immediately upon the achievement of the milestone and 1/48th of the shares vest each month thereafter for three years, not to exceed February 15, 2018, at which time any of such shares remaining unvested will vest. The option is subject to vesting acceleration in the event of certain corporate or change of control transactions.
Billionaire Hedge Funds
